MGNX News and Press, MacroGenics Inc. From 03/14/23

2023-03-14 08:34:09 ET Synaffix has announced the expansion of its license agreement with MacroGenics ( NASDAQ: MGNX ), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The ...

2023-03-10 17:31:23 ET Amid concerns about smaller pharma and biotech companies' exposure to Silicon Valley Bank ( SIVB ), a number of them have disclosed that they have no relationship with the FDIC-shuttered financial institution . Among the larger ones are Cara Therapeu...

2023-03-09 15:59:00 ET Shares of MacroGenics (NASDAQ: MGNX) were up more than 11% as of 3 p.m. EST on Thursday afternoon. The biotech company specializes in monoclonal antibody-based oncology therapies and has one product, Margenza, used in combination with chemotherapy to treat...

2023-03-08 19:42:52 ET MacroGenics ( NASDAQ: MGNX ) said Wednesday it would sell its royalty interest on future global net sales of TZIELD to a wholly-owned subsidiary of DRI Healthcare Trust for up to $200 million. MacroGenics said it would retain its other economic interests...

ROCKVILLE, MD, March 08, 2023 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that it has entered into an agreement to s...

ROCKVILLE, MD, March 07, 2023 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financia...

Summary MacroGenics is a biopharmaceutical company focusing on cancer and autoimmune disorder treatment development with a broad pipeline of product candidates based on proprietary Fc optimization and Dual-Affinity Re-Targeting technology. Lorigerlimab is a bispecific, tetravalent, Fc-b...

MacroGenics ( NASDAQ: MGNX ) will initiate a phase 2 trial of its biologic lorigerlimab later this year after preliminary phase 1 data showed promising results in metastatic castration-resistant prostate cancer (mCRPC). Results showed that nine of 35 patients -- ~26% --...

Twelve of 42 patients (28.6%) in metastatic castration-resistant prostate cancer (mCRPC) cohort achieved ≥ 50% prostate-specific antigen (PSA) reduction (PSA50), including 9 (21.4%) who achieved ≥ 90% PSA reduction (PSA90) Nine of 35 patients (25.7%) with measurable mCRPC achiev...

Summary Healthcare significantly outperformed the broader market last year, after two years of underperforming the S&P 500. When the end to restrictive policy is in sight, then the sector is likely to witness a group rotation to more growth-oriented stocks. Groups like medical d...